Cargando…

Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome

Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individua...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Helen R., Hodgson, Kirsty, Schwalbe, Edward, Coxhead, Jonathan, Sinclair, Naomi, Zou, Xueqing, Cockell, Simon, Husain, Akhtar, Nik-Zainal, Serena, Rajan, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797807/
https://www.ncbi.nlm.nih.gov/pubmed/31624251
http://dx.doi.org/10.1038/s41467-019-12746-w
_version_ 1783459915111596032
author Davies, Helen R.
Hodgson, Kirsty
Schwalbe, Edward
Coxhead, Jonathan
Sinclair, Naomi
Zou, Xueqing
Cockell, Simon
Husain, Akhtar
Nik-Zainal, Serena
Rajan, Neil
author_facet Davies, Helen R.
Hodgson, Kirsty
Schwalbe, Edward
Coxhead, Jonathan
Sinclair, Naomi
Zou, Xueqing
Cockell, Simon
Husain, Akhtar
Nik-Zainal, Serena
Rajan, Neil
author_sort Davies, Helen R.
collection PubMed
description Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multigenerational families and discover recurrent mutations in epigenetic modifiers DNMT3A and BCOR in 29% of benign tumors. Multi-level and microdissected sampling strikingly reveal that many clones with different DNMT3A mutations exist in these benign tumors, suggesting that intra-tumor heterogeneity is common. Integrated genomic, methylation and transcriptomic profiling in selected tumors suggest that isoform-specific DNMT3A2 mutations are associated with dysregulated methylation. Phylogenetic and mutational signature analyses confirm cylindroma pulmonary metastases from primary skin tumors. These findings contribute to existing paradigms of cutaneous tumorigenesis and metastasis.
format Online
Article
Text
id pubmed-6797807
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67978072019-10-21 Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome Davies, Helen R. Hodgson, Kirsty Schwalbe, Edward Coxhead, Jonathan Sinclair, Naomi Zou, Xueqing Cockell, Simon Husain, Akhtar Nik-Zainal, Serena Rajan, Neil Nat Commun Article Patients with CYLD cutaneous syndrome (CCS; syn. Brooke-Spiegler syndrome) carry germline mutations in the tumor suppressor CYLD and develop multiple skin tumors with diverse histophenotypes. Here, we comprehensively profile the genomic landscape of 42 benign and malignant tumors across 13 individuals from four multigenerational families and discover recurrent mutations in epigenetic modifiers DNMT3A and BCOR in 29% of benign tumors. Multi-level and microdissected sampling strikingly reveal that many clones with different DNMT3A mutations exist in these benign tumors, suggesting that intra-tumor heterogeneity is common. Integrated genomic, methylation and transcriptomic profiling in selected tumors suggest that isoform-specific DNMT3A2 mutations are associated with dysregulated methylation. Phylogenetic and mutational signature analyses confirm cylindroma pulmonary metastases from primary skin tumors. These findings contribute to existing paradigms of cutaneous tumorigenesis and metastasis. Nature Publishing Group UK 2019-10-17 /pmc/articles/PMC6797807/ /pubmed/31624251 http://dx.doi.org/10.1038/s41467-019-12746-w Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Davies, Helen R.
Hodgson, Kirsty
Schwalbe, Edward
Coxhead, Jonathan
Sinclair, Naomi
Zou, Xueqing
Cockell, Simon
Husain, Akhtar
Nik-Zainal, Serena
Rajan, Neil
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title_full Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title_fullStr Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title_full_unstemmed Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title_short Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndrome
title_sort epigenetic modifiers dnmt3a and bcor are recurrently mutated in cyld cutaneous syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797807/
https://www.ncbi.nlm.nih.gov/pubmed/31624251
http://dx.doi.org/10.1038/s41467-019-12746-w
work_keys_str_mv AT davieshelenr epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT hodgsonkirsty epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT schwalbeedward epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT coxheadjonathan epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT sinclairnaomi epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT zouxueqing epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT cockellsimon epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT husainakhtar epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT nikzainalserena epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome
AT rajanneil epigeneticmodifiersdnmt3aandbcorarerecurrentlymutatedincyldcutaneoussyndrome